The efficacy and safety of diacerein versus placebo in the treatment of chronic low back pain. Double-blind, randomized, placebo controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210203004

Enrollment

Registered

2021-02-03

Start date

2021-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic low back pain Chronic low back pain, Lumbar spondylosis

Interventions

Treatment group received 50 mg diacerein once daily ,Placebo group received placebo drug 1 capsule once daily

Experimental Drug,Placebo Comparator Other

Treatment group,Placebo group

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: the outpatients who had low back pain more than 12 weeks

Exclusion criteria

Exclusion criteria: Hypersensitivity to diacerein, to similar compounds, NSAIDs or to acetaminophen. Serious concomitant medical illness Prior spinal surgery Epidural steroid injection or facet block within 2 months Glucosamine or chondroitin sulfate within 4 months Antidepressant or tranquilizer drugs treatment Inflammatory joint disease (AS, spondyloarthropathy) GI disease (diarrhea symptoms) Laxative drug therapy Hepatic disease (AST or ALT >=2.5 times) History of malignancy Coronary heart disease Chronic kidney disease Upper gastrointestinal hemorrhage

Design outcomes

Primary

Measure	Time frame
VAS 1, 4, 7 months mm	—

Secondary

Measure	Time frame
Oswestry Low Back Pain Disability Score 1, 4, 7 months Score,SF-36 score 1, 4, 7 months Score,Adverse events 1, 4, 7 months Frequency	—

Countries

Thailand

Contacts

Public ContactPracha Radjaidee

CHIANGMAI UNIVERSITY

0956581169

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026